The cocktail called REGN-COV2 contains a combination of experimental monoclonal antibodies casirivimab and imdevimab, which act in connection with the corona of the virus and prevent its entry into the cells not yet infected to replicate the genetic material, thus controlling the disease.
REGN-COV2 is especially for the elderly, obese people, people suffering from heart diseases, hypertension, chronic lung diseases and HIV/AIDS, for people with diabetes, respiratory, chronic kidney and liver diseases, among other comorbidities, who have a high risk of developing the progression to a serious condition of Covid-19.
According to ANVISA, the cocktail will be restricted to hospitals for out-patient use, that is, for patients with mild symptoms of coronavirus, and it will be administered under prescription only.
The cocktail was authorized to be administered to patients older than 12 years, weighing more than 40 kg, who do not require oxygen supplementation and do not have severe Covid-19 signs.
It will be applied intravenously and must be administered shortly after confirmation, up to 10 days after the onset of symptoms.
ANVISA´s Director General of Medicines and Biological Products Gustavo Silva Santos explained the REGN-COV2 cocktail uses two monoclonal antibodies that act to neutralize the virus, providing other extras to patients.